Liminal Biosciences Plans to Divest its Remaining Non-Core Assets

Liminal BioSciences Inc. is a Canada-based is a development-stage biopharmaceutical company. The Company is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The Company is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.